ABVC BioPharma (NASDAQ:ABVC) Trading 2.5% Higher – Time to Buy?

ABVC BioPharma, Inc. (NASDAQ:ABVC) shares shot up 2.5% during trading on Tuesday . The company traded as high as $1.2598 and last traded at $1.23. Approximately 41,860 shares were traded during mid-day trading, a decline of 79% from the average session volume of 198,254 shares. The stock had previously closed at $1.20.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised ABVC BioPharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 15th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has an average rating of “Sell”.

ABVC BioPharma Stock Performance

The company has a 50-day moving average of $1.37 and a 200-day moving average of $1.47. The firm has a market capitalization of $31.98 million, a price-to-earnings ratio of -3.07 and a beta of 0.54.

ABVC BioPharma (NASDAQ:ABVC) last announced its earnings results on Monday, May 18th. The company reported ($0.06) EPS for the quarter.

Institutional Investors Weigh In On ABVC BioPharma

Large investors have recently made changes to their positions in the stock. Citadel Advisors LLC bought a new stake in ABVC BioPharma in the 3rd quarter valued at $48,000. Millennium Management LLC bought a new position in ABVC BioPharma during the 3rd quarter worth about $60,000. Finally, Geode Capital Management LLC increased its holdings in ABVC BioPharma by 5.8% during the 2nd quarter. Geode Capital Management LLC now owns 110,499 shares of the company’s stock worth $246,000 after purchasing an additional 6,017 shares in the last quarter. Institutional investors own 11.38% of the company’s stock.

About ABVC BioPharma

ABVC BioPharma is a clinical-stage biotechnology company focused on the discovery and development of novel vaccine and immunotherapy candidates for oncology and infectious diseases. The company leverages a proprietary peptide-based platform to identify and synthesize immunogenic epitopes, aiming to stimulate targeted immune responses against tumor-associated and pathogen-derived antigens.

The company’s pipeline includes active immunotherapy programs designed to address a range of cancer indications, along with vaccine candidates targeting bacterial pathogens.